Maintenance immunotherapy with checkpoint inhibition was recently established in the JAVELIN-100 trial, which showed improved survival in patients with advanced bladder cancer treated with maintenance anti–PD-L1 therapy following induction chemotherapy (49). The gene discussed is CD274; the disease is urinary bladder carcinoma.